Q-omics provides the consensus-scored RDH13 profile across patient tissues and cancer cell-line models. RDH13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RDH13 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RDH13 RNA expression shows 19,496 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, and UVM as cancer lineages where RDH13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDH13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDH13 survival associations across molecular data types. RDH13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDH13 RNA expression–survival associations across cancer types. High RDH13 expression shows unfavorable associations in THCA, ACC, UVM and LGG, but favorable associations in KIRP and SCLC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify THCA as the clearest survival context for RDH13 RNA expression.
This table summarizes RDH13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RDH13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDH13 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, STAD, KIRP and CHOL. The THCA box plot shows higher RDH13 RNA expression in normal versus tumor tissue (log2 FC = −0.850, t-test p < 0.001).
This table shows molecular features associated with RDH13 in patient tissues and cancer cell lines. In patient samples, RDH13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RDH13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
